Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some signaling pathways are well defined in HS, the role of TNF-like ligand 1 (TL1A) is not well understood. A group of researchers has investigated the association of TL1A with HS, as well as its association with other cytokine networks.
Vidac Pharma Holding plc has announced the initiation of an in vivo preclinical program to evaluate the potential of its hexokinase 2 (HK2)/voltage-dependent anion channel (VDAC)-targeting approach in psoriasis.
Dewpoint Therapeutics Inc. has selected a development candidate in its MYC program. The first-in-class small molecule is designed to disrupt MYC-driven oncogenic transcription by modulating the aberrant biomolecular condensates that organize transcriptional control in cancer cells.
Tau is an intrinsically disordered protein that regulates the stability and dynamics of microtubules in physiological conditions. Recent work has revealed the involvement of tau in various neuronal processes. Researchers from the University of California and collaborators aimed to systematically investigate the cellular factors that control the accumulation of tau aggregates in human neurons.
The malfunction of lymphatic drainage that occurs in lymphedema leads to excessive cholesterol accumulation in the affected skin and lymphatic vessels, causing inflammation and fibrosis. However, surgery and the chemical reduction of accumulated cholesterol with cyclodextrin reduce inflammation and regenerate lymphatic vessels. Cholesterol is a potential therapeutic target for treating lymphedema, according to this study published on Feb. 11, 2026, in Nature by Veronique Angeli and her colleagues.
Aquinnah Pharmaceuticals Inc. has disclosed new microtubule-associated protein τ (PHF-τ; MAPT) aggregation inhibitors designed for use in the treatment of Alzheimer’s disease and frontotemporal dementia.
Kunshan Xinyunda Biotechnology Co. Ltd. has discovered antibody-drug conjugates (ADCs) consisting of antibodies covalently linked to cytotoxic drugs potentially useful for the treatment of cancer.
Scientists from Shenzhen Medical Academy of Research and Translation and the Southern Medical University have synthesized solute carrier family 22 member 12 (SLC22A12; URAT1) inhibitors. They are reported to be useful for the treatment of kidney injury, hyperuricemia and gout.
Bivision Pharmaceuticals (Shanghai) Co. Ltd. has identified cyclic peptides targeting fibroblast activating protein α (FAP) reported to be useful for the treatment of cancer.
Researchers from Eurofarma Laboratorios SA and Universidade Federal do Rio de Janeiro – Macae havs synthesized histone deacetylase 6 (HDAC6) inhibitors reported to be potentially useful for the treatment of cancer.
RSS
